Drug firm Lupin has strengthened its brand portfolio in the US market with the introduction of its Methergine oral tablets used for the prevention and management of excess blood loss after delivery, in the US.
The company had acquired oral methylergonovine maleate (Methergine) earlier this year, Lupin said in a statement.
"The re-introduction of Methergine is a proud moment for Lupin, but also an important moment for expectant mothers across the country to feel confident in care options," Lupin Pharmaceuticals Inc President Paul McGarty said.
The tablets are used "for the prevention and management of postpartum hemorrhage (PPH)", Lupin said.
"The United States is Lupin's largest market and contributed 45 per cent to the company's revenue during financial year 2014-15," a company spokesperson told PTI.
Methergine is a registered trademark of Novartis AG, the company said.
Shares of Lupin today closed at Rs 1,577.15 per scrip on BSE, up 0.44 per cent from its previous close.
